The drug repurposing service providers market is estimated to be worth USD 1.2 billion in 2030, predicts Roots Analysis

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

Roots Analysis is pleased to announce the publication of its recent study, titled, “Drug Repurposing Service Providers Market, 2020-2030.”

The report features an extensive study of the current market landscape and future opportunities for players offering services for repurposing / repositioning / reprofiling of drug candidates. It features an in-depth analysis, highlighting the capabilities of various service providers engaged in this domain. In addition to other elements, the study includes:

• A detailed assessment of the current market landscape of companies offering drug repurposing services.
• Elaborate profiles of key players that specialize in offering services for the development of repurposed drugs.
• An analysis of the partnerships that have been established in this domain, in the recent past.
• An analysis of the initiatives of big biopharma players engaged in this domain.
• A detailed analysis of more than 1,700 terminated / withdrawn / suspended clinical studies of the drug candidates.
• A detailed analysis on the cost saving potential of drug repurposing approaches, as compared to the traditional de novo drug development methods.
• A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
• The dataset features a variety of CRO, big data / analytics and technology-based service providers, offering repurposing services by using different type of repurposing approaches and drug molecules
• Over 1,700  discontinued clinical studies of therapeutics can be considered as potential candidates for repurposing
• In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, service providers are actively exploring the therapeutic potential of the existing approved drugs by providing the necessary support to drug developers in identifying / predicting prospective drug candidates for repurposing.
• Over time, recent initiatives have been undertaken by big pharma players across the world for the discovery and development of repurposed drugs

• Type of Repurposing Approaches
• Disease-centric approach
• Target-centric approach
• Drug-centric approach
• Therapeutic Area
• Same Therapeutic Area
• Different Therapeutic Area
• Type of Drug Molecule
• Biologics
• Small Molecule
• Key Geographical Region
• North America
• Europe
• Asia-Pacific

Key companies covered in the report

• Auxillis Pharma
• ChemBio Discovery Solutions
• Excelra
• GVK Bio
• Iris Pharma
• Lantern Pharma
• PanXome
• Pharmacelera
• Physiogenex
• Smart Pharma
• Socium
• SOM Biotech

For more information please click on the following link:

https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

Other Recent Offerings

1. Peptides and Macrocycle Drug Discovery: Services and Platforms Market, 2020 - 2030
2. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
3. Antibody Contract Manufacturing Market, 2020 - 2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]